Literature DB >> 21927543

An improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol (D-142).

Bhaskar Gopishetty1, Sanjib Gogoi, Aloke Dutta.   

Abstract

Triple monoamine reuptake inhibitors have been implicated in the development of a new generation of antidepressants with higher efficacy than the currently existing therapies. In this paper, we have developed an alternative efficient synthetic route for triple n class="Chemical">monoamine reuptake inhibitor D-142 in 18.5% overall yield in 11 steps starting from diphenylmethane. D-142 was developed by us recently. The key step of the present synthetic strategy is the preferential formation of a bromohydrin from olefin via a cis-bromoinum intermediate, which introduced significant efficiency in the overall synthesis. Furthermore, we have developed an efficient way to recycle the optically active intermediate diol back to the desired chiral epoxide.

Entities:  

Year:  2011        PMID: 21927543      PMCID: PMC3171748          DOI: 10.1016/j.tetasy.2011.05.012

Source DB:  PubMed          Journal:  Tetrahedron Asymmetry        ISSN: 0957-4166


  17 in total

1.  Asymmetric catalysis with water: efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis.

Authors:  M Tokunaga; J F Larrow; F Kakiuchi; E N Jacobsen
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

Review 2.  Third-generation antidepressants.

Authors:  R M Pinder; J H Wieringa
Journal:  Med Res Rev       Date:  1993-05       Impact factor: 12.944

3.  Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.

Authors:  Amanda M Shaw; Mona Boules; Yiqun Zhang; Katrina Williams; Jessica Robinson; Paul R Carlier; Elliott Richelson
Journal:  Eur J Pharmacol       Date:  2006-10-17       Impact factor: 4.432

Review 4.  Antidepressants and the brain.

Authors:  P Delgado; F Moreno
Journal:  Int Clin Psychopharmacol       Date:  1999-05       Impact factor: 1.659

5.  Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner.

Authors:  Shijun Zhang; Juan Zhen; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

6.  D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.

Authors:  Aloke K Dutta; Balaram Ghosh; Swati Biswas; Maarten E A Reith
Journal:  Eur J Pharmacol       Date:  2008-05-20       Impact factor: 4.432

7.  An oxidation and ring contraction approach to the synthesis of (+/-)-1-deoxynojirimycin and (+/-)-1-deoxyaltronojirimycin.

Authors:  Sharan K Bagal; Stephen G Davies; James A Lee; Paul M Roberts; Angela J Russell; Philip M Scott; James E Thomson
Journal:  Org Lett       Date:  2010-01-01       Impact factor: 6.005

Review 8.  The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.

Authors:  N Brunello; J Mendlewicz; S Kasper; B Leonard; S Montgomery; J Nelson; E Paykel; M Versiani; G Racagni
Journal:  Eur Neuropsychopharmacol       Date:  2002-10       Impact factor: 4.600

Review 9.  Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics.

Authors:  B J Goldstein; P J Goodnick
Journal:  J Psychopharmacol       Date:  1998       Impact factor: 4.153

10.  Schimke immunoosseous dysplasia: defining skeletal features.

Authors:  Kshamta B Hunter; Thomas Lücke; Jürgen Spranger; Sarah F Smithson; Harika Alpay; Jean-Luc André; Yumi Asakura; Radovan Bogdanovic; Dominique Bonneau; Robyn Cairns; Karlien Cransberg; Stefan Fründ; Helen Fryssira; David Goodman; Knut Helmke; Barbara Hinkelmann; Guiliana Lama; Petra Lamfers; Chantal Loirat; Silvia Majore; Christy Mayfield; Bertram F Pontz; Cristina Rusu; Jorge M Saraiva; Beate Schmidt; Lawrence Shoemaker; Sabine Sigaudy; Natasa Stajic; Doris Taha; Cornelius F Boerkoel
Journal:  Eur J Pediatr       Date:  2009-12-15       Impact factor: 3.183

View more
  4 in total

1.  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.

Authors:  Soumava Santra; Horrick Sharma; Seenuvasan Vedachalam; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2014-12-25       Impact factor: 3.641

2.  Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.

Authors:  Horrick Sharma; Soumava Santra; Joy Debnath; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2013-11-19       Impact factor: 3.641

3.  Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.

Authors:  Soumava Santra; Sanjib Gogoi; Bhaskar Gopishetty; Tamara Antonio; Juan Zhen; Maarten E A Reith; Aloke K Dutta
Journal:  ChemMedChem       Date:  2012-10-11       Impact factor: 3.466

4.  Highly enantioselective production of (R)-halohydrins with whole cells of Rhodotorula rubra KCh 82 culture.

Authors:  Tomasz Janeczko; Monika Dymarska; Edyta Kostrzewa-Susłow
Journal:  Int J Mol Sci       Date:  2014-12-04       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.